Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

225
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
225
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

370
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
370
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

36
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
36
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

450
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
450
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

172
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
172
Operant Conditioning Intervention01:24

Operant Conditioning Intervention

56
Operant conditioning serves as a foundational principle in therapeutic interventions aimed at modifying maladaptive behaviors. Central to this approach is the notion that behaviors, both adaptive and maladaptive, are learned through reinforcement. By analyzing the environmental factors that reinforce problematic behaviors, clinicians can design interventions to weaken these reinforcements and replace maladaptive behaviors with healthier alternatives.
In operant conditioning, behaviors that are...
56

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.

Nursing for women's health·2020
Same author

Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.

Nursing for women's health·2020
Same author

Lasmiditan Is a New Option for Acute Migraine Treatment.

Nursing for women's health·2020
Same author

Measles-What's Old Is New Again.

Nursing for women's health·2020
Same author

New Osteoporosis Treatment Means New Bone Formation.

Nursing for women's health·2019
Same author

A New Year-Long Combination Hormonal Contraceptive.

Nursing for women's health·2019

Related Experiment Video

Updated: Jun 25, 2025

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
06:39

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Published on: June 13, 2021

3.0K

First Oral Treatment Specific for Postpartum Depression.

Kala K Blakely

    Nursing for Women'S Health
    |May 20, 2024
    PubMed
    Summary

    A new oral medication, zuranolone (Zurzuvae), offers a 2-week treatment for postpartum depression. This breakthrough provides an accessible outpatient option for mothers experiencing this common perinatal mood disorder.

    Keywords:
    Zurzuvaedepressionmental healthmood disorderperipartum depressionpostpartum depressionpregnancyzuranolone

    More Related Videos

    Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents
    07:30

    Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents

    Published on: June 10, 2013

    24.8K
    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
    04:29

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

    Published on: January 7, 2019

    28.6K

    Related Experiment Videos

    Last Updated: Jun 25, 2025

    Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
    06:39

    Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

    Published on: June 13, 2021

    3.0K
    Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents
    07:30

    Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents

    Published on: June 10, 2013

    24.8K
    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
    04:29

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

    Published on: January 7, 2019

    28.6K

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Psychiatry

    Background:

    • Postpartum depression (PPD) is a prevalent perinatal mood disorder affecting many mothers.
    • Existing treatments for PPD can be lengthy and may require significant lifestyle adjustments.

    Purpose of the Study:

    • To provide an overview of zuranolone, a novel oral medication for postpartum depression.
    • To discuss its mechanism of action, indications, and potential adverse effects.

    Main Methods:

    • Review of the FDA approval and pharmacological data for zuranolone.
    • Analysis of its proposed mechanism as a positive allosteric modulator of GABA-A receptors.
    • Examination of its outpatient, 2-week oral administration regimen.

    Main Results:

    • Zuranolone (Zurzuvae) received FDA approval in August 2023 as the first oral medication specifically for PPD.
    • It functions similarly to benzodiazepines by modulating GABA-A receptors.
    • The short-course treatment allows for outpatient care, potentially improving adherence and daily functioning.

    Conclusions:

    • Zuranolone represents a significant advancement in the pharmacological treatment of postpartum depression.
    • Its novel mechanism and convenient administration offer a new therapeutic option for affected women.
    • Implications for nursing practice include patient education on administration, monitoring for adverse reactions, and supporting outpatient management.